DaVita (NYSE:DVA) Sets New 1-Year High – Should You Buy?

DaVita Inc. (NYSE:DVA) shares reached a new 52-week high during trading on Monday . The stock traded as high as $236.51 and last traded at $234.7880, with a volume of 830603 shares traded. The stock had previously closed at $234.91.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Truist Financial lifted their price objective on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Barclays boosted their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Finally, UBS Group increased their target price on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average price target of $199.17.

DaVita Trading Up 0.8%

The company has a 50-day moving average of $196.44 and a 200-day moving average of $156.56. The company has a market capitalization of $15.21 billion, a price-to-earnings ratio of 22.01, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the company earned $2.00 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita Inc. will post 15.07 EPS for the current year.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On DaVita

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its position in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after acquiring an additional 636,191 shares during the period. Norges Bank purchased a new position in shares of DaVita in the fourth quarter worth about $49,164,000. Corient Private Wealth LLC raised its stake in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after purchasing an additional 335,809 shares during the last quarter. Man Group plc lifted its holdings in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in DaVita by 2,905.7% in the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock valued at $30,324,000 after buying an additional 220,628 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.